Ysios Capital

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.

Aelix Therapeutics SL is a biotechnology company based in Barcelona, Spain, focused on developing therapeutic vaccines and immunotherapies for the treatment of HIV infection. Established in 2015, Aelix Therapeutics emerged as a spin-off from HIVACAT, a Catalan initiative aimed at creating effective HIV vaccines. The company is led by a team of experienced professionals in the fields of HIV and biotechnology, including Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell, and Jordi Naval. Aelix Therapeutics leverages innovative immunogen designs to enhance its therapeutic approaches and has established partnerships that provide access to extensive cohorts of HIV-infected patients across various continents, facilitating clinical research and development. The company's vaccine strategy is based on a T-cell immunogen that has the potential to elicit strong immune responses, aiming to transform the treatment landscape for HIV and improve patient outcomes.

Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.

Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. As a spin-off from the ICREA and Advanced Studies and the IRB Institute for Research in Biomedicine, Ona Therapeutics focuses on the discovery and development of therapeutic biologics that target tumor metastatic-initiating cells and lipid metabolism. The company's innovative therapies aim to block pathways related to fat metabolism in animal models of cancer and inhibit the cells responsible for metastasis. This approach has the potential to prevent the development of malignant tumors and eliminate existing ones, offering new treatment options for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

Anaconda Biomed, founded in 2015 and based in Barcelona, Spain, is an innovative medical technology company focused on developing advanced healthcare devices for the treatment of acute ischemic stroke (AIS). The company specializes in neuro-thrombectomy systems, notably the ANCD BRAIN™, a third-generation stented aspiration thrombectomy system. This system is designed to perform mechanical thrombectomies using a combination of a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. When deployed, the stent retriever expands to conform to the artery, effectively halting blood flow and enabling the complete extraction of thrombus without fragmentation. This technology aims to provide immediate treatment for stroke patients, significantly reducing the risk of fatality.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Anaconda Biomed, founded in 2015 and based in Barcelona, Spain, is an innovative medical technology company focused on developing advanced healthcare devices for the treatment of acute ischemic stroke (AIS). The company specializes in neuro-thrombectomy systems, notably the ANCD BRAIN™, a third-generation stented aspiration thrombectomy system. This system is designed to perform mechanical thrombectomies using a combination of a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. When deployed, the stent retriever expands to conform to the artery, effectively halting blood flow and enabling the complete extraction of thrombus without fragmentation. This technology aims to provide immediate treatment for stroke patients, significantly reducing the risk of fatality.

STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.

Inbiomotion SL, a personalized medicine company, develops biomarkers that predict bone metastasis to improve the quality of life of cancer patients. The company focuses on the development of a diagnostic assay based on a selective single gene/protein biomarker that predicts those patients at risk of suffering bone-specific metastases from primary tumors. It develops biomarker in breast cancer primary tumors for predicting the risk of bone relapse. Inbiomotion SL was founded in 2010 and is based in Barcelona, Spain.

Aelix Therapeutics SL is a biotechnology company based in Barcelona, Spain, focused on developing therapeutic vaccines and immunotherapies for the treatment of HIV infection. Established in 2015, Aelix Therapeutics emerged as a spin-off from HIVACAT, a Catalan initiative aimed at creating effective HIV vaccines. The company is led by a team of experienced professionals in the fields of HIV and biotechnology, including Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell, and Jordi Naval. Aelix Therapeutics leverages innovative immunogen designs to enhance its therapeutic approaches and has established partnerships that provide access to extensive cohorts of HIV-infected patients across various continents, facilitating clinical research and development. The company's vaccine strategy is based on a T-cell immunogen that has the potential to elicit strong immune responses, aiming to transform the treatment landscape for HIV and improve patient outcomes.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.

Inbiomotion SL, a personalized medicine company, develops biomarkers that predict bone metastasis to improve the quality of life of cancer patients. The company focuses on the development of a diagnostic assay based on a selective single gene/protein biomarker that predicts those patients at risk of suffering bone-specific metastases from primary tumors. It develops biomarker in breast cancer primary tumors for predicting the risk of bone relapse. Inbiomotion SL was founded in 2010 and is based in Barcelona, Spain.

STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.

SabirMedical S.L. is a biomedical research and development company based in Barcelona, Spain, founded in 2007. The company specializes in developing innovative technologies for diagnostics and patient care, particularly in the area of cardiovascular monitoring. Its offerings include non-invasive blood pressure monitoring systems that utilize pulse oximetry, designed for hospital, ambulatory, and home use. SabirMedical operates from the Bioincubator PCB-Santander space at Barcelona Science Park, emphasizing its commitment to advancing healthcare through technology.